Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
100.15
+1.32 (1.34%)
Sep 22, 2026, 2:23 PM EDT - Market open
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Rhythm Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $138.59. The average 1-year stock price forecast is 38.38% higher than the current stock price, while the lowest is $105 (+4.84%) and the highest is $160 (+59.76%).
Price Target: $138.59 (+38.38%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Sep 17, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $155 | Buy | Maintains | $155 | +54.77% | Sep 15, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $133 | Buy | Initiates | $133 | +32.80% | Sep 14, 2026 |
| Deutsche Bank | Deutsche Bank | Hold Initiates $120 | Hold | Initiates | $120 | +19.82% | Aug 28, 2026 |
Financial Forecast
Revenue This Year
313.30M
from 189.76M
Increased by 65.10%
Revenue Next Year
558.34M
from 313.30M
Increased by 78.21%
EPS This Year
-3.10
from -3.11
EPS Next Year
-0.61
from -3.10
EPS and Forward PE are based on non-GAAP adjusted numbers.